 Your new post is loading...
Your new post is loading...
Scoop.it!
Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatmen... 
No comment yet.
Sign up to comment
Scoop.it!
A brief overview of definitions and a description of microglial ontogeny.
Scoop.it!
Neurology. 2015 Mar 31;84(13):1362-8. doi: 10.1212/WNL.0000000000001420. Epub 2015 Mar 4.
Scoop.it!
Questions arise about monitoring lymphocyte counts with Tecfidera.
Scoop.it!
Immunology and Immunotherapy in Brain Tumors — Immune Failure and Potential Counteractions | InTechOpen, Published on: 2015-03-25. Authors: Soliman Oushy and Michael W. Graner
Scoop.it!
Curr Treat Options Neurol. 2015 Apr;17(4):344. doi: 10.1007/s11940-015-0344-7.
Scoop.it!
Front Immunol. 2015 Mar 11;6:106. doi: 10.3389/fimmu.2015.00106. eCollection 2015. Review
Scoop.it!
Correspondence from The New England Journal of Medicine — PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Scoop.it!
Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs based on the myelin basic protein 83–99 (MBP83–99) immunodominant epitope conjugated to reduced mannan via the (KG)5 and keyhole limpet hemocyanin (KLH) bridge, respectively, were evaluated for their biological/immunological profiles in SJL/J mice. Of all the peptide analogs tested, linear MBP83–99(F91) and linear MBP83–99(Y91) conjugated to reduced mannan via a (KG)5 linker and cyclic MBP83–99(F91) conjugated to reduce mannan via KLH linker, yielded the best immunological profile and constitute novel candidates for further immunotherapeutic studies against MS in animal models and in human clinical trials. Via Denis Hudrisier, Krishan Maggon
Krishan Maggon 's curator insight,
April 8, 2015 12:56 AM
ORIGINAL RESEARCH ARTICLEFront. Immunol., 07 April 2015 | doi: 10.3389/fimmu.2015.00136Mannosylated linear and cyclic single amino acid mutant peptides using a small 10 amino acid linker constitute promising candidates against multiple sclerosisStephanie Day1, Theodore Tselios2, Maria-Eleni Androutsou2,3, Anthi Tapeinou2, Irene Frilligou2, Lily Stojanovska4, John Matsoukas2,3 and Vasso Apostolopoulos4*1Immunology and Vaccine Laboratory, Burnet Institute, Melbourne, VIC, Australia2Department of Chemistry, University of Patras, Patras, Greece3Eldrug S.A., Patras, Greece4Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia
Scoop.it!
These are exciting times in the treatment of multiple sclerosis says Lesley Murray advanced pharmacist for neurosciences at the Southern General Hospital in Glasgow For
Scoop.it!
Read more about Vaccinex Pre-clinical data on VX15/2503 for Multiple Sclerosis
Scoop.it!
Choroid plexus tumors are rare intraventricular papillary neoplasms derived from choroid plexus epithelium, which account for approximately 2% to 4% of intracranial tumors in children and 0.5% in adults.
Scoop.it!
"Lessons From Anti-VEGF & Anti-VEGF Receptor Trials in Patients With Glioblastoma" JCO http://t.co/3hmx8iqDWt
|
Scoop.it!
Monoclonal antibody (mAb) treatment has revolutionized the approach to many diseases and represents a fast-growing area of drug development.1,2 They are composed of immunoglobulin G (IgG) isotypes, divided into four subclasses.3 In 1986, the US... Via Krishan Maggon
Scoop.it!
Researchers in Sweden at Lund University published new research on the role of the intestinal barrier in the autoimmune disease multiple sclerosis (MS).
Scoop.it!
The creation and progression of multiple sclerosis present scientists with many riddles. Now researchers from the universities of Würzburg and Amsterdam have succeeded in resolving an apparent contradiction in the findings to date.
Scoop.it!
Lemtrada (alemtuzumab) injection is approved for the management of relapsing forms of multiple sclerosis (MS). In general, use of Lemtrada should be limited to patients with MS who have not had therapeutic success with 2 or more prior treatments.
Scoop.it!
Author Summary Cryptococcal meningitis is a severe opportunistic infection, estimated to kill several hundred thousand HIV-infected individuals each year.
Scoop.it!
Learn how boosting the immune system with a tetanus vaccine before administering a dendritic cell vaccine enhances glioblastoma multiforme patients immune response leading to increased survival.
Scoop.it!
MS researchers are focusing on the content of the gut’s microbiome as a possible contributor to the body’s autoimmune attack on its nervous system
Scoop.it!
Dysregulation of the complement system is evident in many CNS diseases but mechanisms regulating complement activation in the CNS remain unclear. Via Krishan Maggon
Krishan Maggon 's curator insight,
April 7, 2015 2:35 AM
Citation: Aeinehband S, Lindblom RPF, Al Nimer F, Vijayaraghavan S, Sandholm K, et al. (2015) Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis. PLoS ONE 10(4): e0122048. doi:10.1371/journal.pone.0122048
Scoop.it!
RT @MDABrainSpine: How we're using #immunotherapy to treat #glioblastoma http://t.co/CNG3AhlhmL #cancerfilm #BrainTumorThursday via @MDAnd…
Scoop.it!
After examining more than 3,500 donated brains, scientists have gathered evidence to suggest that a rogue protein, tau, which has long been suspected to play a role in the development of Alzheimer’s, is the major driver of cognitive decline in this...
Scoop.it!
Read About How a New Purification Method Promises Affordable Antibody Production For Diseases Like MS.
Scoop.it!
“Molecular national selfie” combines genetics with historical and medical data.
|
